Hoadley Harris, MD
Family Medicine · Fargo, NDNPI 1811991607
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,892 of the $9,909 with a category attached, or 69.6%. It is spread thinly across 55 manufacturers, the largest accounting for just 23.1%. Reporting peaked in 2023 at $2,839 and has fallen 69.7% since, to $859 in 2025. Among family medicine clinicians in ND with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 405 payments — averaging $24.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Janssen Research & Development, LLC$2K
- Merck$692
- Lilly USA, LLC$680
- Sanofi-aventis U.S. LLC$379
- AbbVie$333
- plus $4K from 49 others
Across 140 payments — averaging $5855.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$277K
- Sanofi Pasteur Inc.$243K
- AstraZeneca$198K
- Janssen Research & Development, LLC$88K
- Alnylam Pharmaceuticals Inc.$9K
- Astrazeneca UK Limited$5K
What the payments were for
- Speaking & faculty fees$130%
- Travel & lodging$2,97130%
- Food & beverage$6,89270%
- Education$330%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$1,713
- SYMPLICITY G3$129
How this compares
$9,909 in reported general payments places this provider in the 95th percentile of 337 family medicine providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 154 | $167,812 |
| EliquisApixaban | 86 | $87,096 |
| Repatha SureclickEvolocumab | 115 | $84,086 |
| FarxigaDapagliflozin Propanediol | 55 | $34,878 |
| OzempicSemaglutide | 24 | $30,822 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $19,684 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $10,531 |
| NexlizetBempedoic Acid/Ezetimibe | 13 | $9,816 |
| VascepaIcosapent Ethyl | 29 | $7,686 |
| Ezetimibe | 289 | $6,130 |
| Atorvastatin Calcium | 381 | $4,301 |
| Xigduo XrDapaglifloz Propaned/Metformin | 27 | $3,995 |
| Tamsulosin Hcl | 164 | $3,191 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $2,698 |
| Rosuvastatin Calcium | 254 | $2,608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $680 | $167,812154 claims |
| PfizerEliquis | $108 | $87,09686 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $2,293 | $45,40871 claims |
| Novo NordiskOzempic | $310 | $30,82224 claims |
| GSKTrelegy Ellipta | $77 | $19,68418 claims |
| Esperion Therapeutics, Inc.Nexlizet | $147 | $9,81613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 337 family medicine providers in North Dakota.
Other family medicine in Fargo
- Spencer BerryFargo$81K
- Stuart TopleyFargo$24K
- Joel SchockFargo$9K
- Tyson WilliamsFargo$3K
- Jennifer BrottlundFargo$1K
- Richard VetterWest Fargo$294K
- Thomas ThorsonMandan$241K
- Gregory GreekGrand Forks$216K
- Katherine NeubauerWest Fargo$160K
- Eric JohnsonGrand Forks$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.